86 related articles for article (PubMed ID: 9757652)
21. [Tumor markers in patients with head-neck carcinomas].
Walther EK; Dahlmann N; Gorgulla HT
Laryngorhinootologie; 1990 May; 69(5):271-4. PubMed ID: 2354022
[TBL] [Abstract][Full Text] [Related]
22. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
Ma S; Shen L; Qian N; Chen K
Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
[TBL] [Abstract][Full Text] [Related]
23. Tumor markers and lymphatic metastasis in head and neck cancer patients.
Büntzel J; Hornig A; Glatzel M; Micke O; Bruns F; Schäfer U; Fröhlich D
Anticancer Res; 2005; 25(3A):1539-42. PubMed ID: 16033056
[TBL] [Abstract][Full Text] [Related]
24. [A case of laryngeal glandular cancer].
Wojdas A; Adamiak G; Hermanowski M; Jurkiewicz D
Otolaryngol Pol; 1995; 49 Suppl 20():420-3. PubMed ID: 9454197
[TBL] [Abstract][Full Text] [Related]
25. CYFRA 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer.
Wollenberg B; Jan V; Schmit UM; Hofmann K; Stieber P; Fateh-Moghadam A
Anticancer Res; 1996; 16(5B):3117-24. PubMed ID: 8920778
[TBL] [Abstract][Full Text] [Related]
26. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
Ebert W; Muley T; Drings P
Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
[TBL] [Abstract][Full Text] [Related]
27. Significance of tumour markers in nasopharyngeal carcinoma.
Kuo WR; Tsai SM; Jong SB; Juan KH
J Otolaryngol; 1996 Feb; 25(1):32-6. PubMed ID: 8816107
[TBL] [Abstract][Full Text] [Related]
28. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
29. Vascular endothelial growth factor a and proliferation marker in prediction of lymph node metastasis in oral and pharyngeal squamous cell carcinoma.
Boonkitticharoen V; Kulapaditharom B; Leopairut J; Kraiphibul P; Larbcharoensub N; Cheewaruangroj W; Chintrakarn C; Pochanukul L
Arch Otolaryngol Head Neck Surg; 2008 Dec; 134(12):1305-11. PubMed ID: 19075127
[TBL] [Abstract][Full Text] [Related]
30. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
31. Values and limits of combined use of 4 tumor markers (CEA, TPA, NSE and SCC) in un-treated patients with lung cancer.
Cuomo A; Capra R; Greco S; Cacciani GC; Greco F; Franchini D; Bonelli P; Gavaruzzi G; Ugolotti G
Acta Biomed Ateneo Parmense; 1993; 64(5-6):171-84. PubMed ID: 7992555
[No Abstract] [Full Text] [Related]
32. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
33. [Gastrointestinal cancer].
Takahashi Y
Gan To Kagaku Ryoho; 2004 Aug; 31(8):1275-9. PubMed ID: 15332558
[TBL] [Abstract][Full Text] [Related]
34. [Tumor markers used in the diagnosis, monitoring, treatment, and prognosis head and neck cancer].
Kopczyński P; Flieger R
Pol Merkur Lekarski; 2013 Jul; 35(205):37-8. PubMed ID: 23984603
[TBL] [Abstract][Full Text] [Related]
35. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
Lai IR; Lee WJ; Huang MT; Lin HH
Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
Spinazzi A; Soresi E; Boffi R; Nonis A; Noseda A; Cobelli S; Scanni A
Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383
[TBL] [Abstract][Full Text] [Related]
37. The tumor markers CEA, TPA and CA 19-9 in gastric cancer.
Putzki H; Reichert B; Jablonski M; Heymann H
Dtsch Z Verdau Stoffwechselkr; 1988; 48(3-4):145-8. PubMed ID: 3234297
[TBL] [Abstract][Full Text] [Related]
38. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
[TBL] [Abstract][Full Text] [Related]
39. [Clinical evaluation of combination assay of tumor markers in primary lung cancer patients].
Hatakeyama S; Nagai A; Kioi S; Arakawa M
Nihon Kyobu Shikkan Gakkai Zasshi; 1990 Aug; 28(8):1053-8. PubMed ID: 2173801
[TBL] [Abstract][Full Text] [Related]
40. Comparison of alpha-fetoprotein with some other tumour markers in Malaysians with hepatocellular carcinoma.
Lopez JB; Balasegaram M; Timor J; Thambyrajah V
Malays J Pathol; 1997 Jun; 19(1):53-8. PubMed ID: 10879242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
